- Home
- HPE vs REGN Comparison
HPE vs REGN Comparison
Compare HPE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HPE | REGN |
|---|---|---|
| Founded | 1939 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6B | 68.6B |
| IPO Year | 2015 | 1995 |
Fundamental Metrics
Financial Performance| Metric | HPE | REGN |
|---|---|---|
| Price | $42.90 | $648.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 25 |
| Target Price | $26.82 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 19.8M | 986.6K |
| Earning Date | 06-02-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.01% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 0.75 | ★ 6.75 |
| Revenue | ★ $34,296,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $20.37 | $12.45 |
| Revenue Next Year | $5.67 | $10.13 |
| P/E Ratio | ★ $57.18 | $96.34 |
| Revenue Growth | 13.84 | ★ 20.82 |
| 52 Week Low | $19.64 | $541.00 |
| 52 Week High | $64.25 | $821.11 |
Technical Indicators
Market Signals| Indicator | HPE | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 57.26 |
| Support Level | $20.58 | $593.21 |
| Resistance Level | $50.45 | $664.00 |
| Average True Range (ATR) | 2.37 | 14.91 |
| MACD | -1.28 | 6.95 |
| Stochastic Oscillator | 23.52 | 86.77 |
Price Performance
Historical ComparisonAbout HPE Hewlett Packard Enterprise Company
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.